...The companies partnered to develop and commercialize predictive histone biomarkers tests using PrognosDx's epigenetic technology with...
...Accium's accelerator mass spectrometry technology. Details were not disclosed. Accium BioSciences Inc. , Seattle, Wash. PrognosDx Health Inc....

...PrognosDx received exclusive, worldwide rights to the university's IP covering histone modification technology. PrognosDx is developing...
...for cancer and other diseases based on histone modification patterns. Further terms were not disclosed. PrognosDx Health Inc....